Danaher（1DHR）株式概要ダナハーコーポレーションは、米国、中国、および国際的な専門、医療、研究、工業製品およびサービスの設計、製造、販売を行っている。 詳細1DHR ファンダメンタル分析スノーフレーク・スコア評価5/6将来の成長2/6過去の実績1/6財務の健全性5/6配当金3/6報酬当社が推定した公正価値より24.8%で取引されている 収益は年間19.89%増加すると予測されています アナリストらは、株価が43%上昇するだろうとほぼ一致している。 リスク分析リスクチェックの結果、1DHR 、リスクは検出されなかった。すべてのリスクチェックを見る1DHR Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€148.704.7% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture032b2016201920222025202620282031Revenue US$32.3bEarnings US$4.8bAdvancedSet Fair ValueView all narrativesDanaher Corporation 競合他社Fine Foods & Pharmaceuticals N.T.MSymbol: BIT:FFMarket cap: €199.5mThermo Fisher ScientificSymbol: NYSE:TMOMarket cap: US$167.9bRecordati Industria Chimica e FarmaceuticaSymbol: BIT:RECMarket cap: €10.5bWuXi AppTecSymbol: SHSE:603259Market cap: CN¥315.9b価格と性能株価の高値、安値、推移の概要Danaher過去の株価現在の株価US$148.7052週高値US$205.5052週安値US$140.50ベータ0.841ヶ月の変化-9.47%3ヶ月変化-16.56%1年変化-9.30%3年間の変化-30.38%5年間の変化-28.61%IPOからの変化14.00%最新ニュースBoard Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 7 highly experienced directors. Independent Director A. Sanders was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 07Danaher Corporation announces Quarterly dividend, payable on July 31, 2026Danaher Corporation announced Quarterly dividend of USD 0.4000 per share payable on July 31, 2026, ex-date on June 26, 2026 and record date on June 26, 2026.Buy Or Sell Opportunity • Mar 29Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 19% to €159. The fair value is estimated to be €199, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 18%. For the next 3 years, revenue is forecast to grow by 5.8% per annum. Earnings are also forecast to grow by 15% per annum over the same time period.お知らせ • Mar 26Danaher Corporation, Annual General Meeting, May 05, 2026Danaher Corporation, Annual General Meeting, May 05, 2026.お知らせ • Mar 21Danaher Corporation to Report Q1, 2026 Results on Apr 21, 2026Danaher Corporation announced that they will report Q1, 2026 results at 6:00 AM, US Eastern Standard Time on Apr 21, 2026お知らせ • Feb 25Danaher Corporation Announces Quarterly Dividend, Payable on April 24, 2026Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 24, 2026 to holders of record on March 27, 2026.最新情報をもっと見るRecent updatesBoard Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 7 highly experienced directors. Independent Director A. Sanders was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 07Danaher Corporation announces Quarterly dividend, payable on July 31, 2026Danaher Corporation announced Quarterly dividend of USD 0.4000 per share payable on July 31, 2026, ex-date on June 26, 2026 and record date on June 26, 2026.Buy Or Sell Opportunity • Mar 29Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 19% to €159. The fair value is estimated to be €199, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 18%. For the next 3 years, revenue is forecast to grow by 5.8% per annum. Earnings are also forecast to grow by 15% per annum over the same time period.お知らせ • Mar 26Danaher Corporation, Annual General Meeting, May 05, 2026Danaher Corporation, Annual General Meeting, May 05, 2026.お知らせ • Mar 21Danaher Corporation to Report Q1, 2026 Results on Apr 21, 2026Danaher Corporation announced that they will report Q1, 2026 results at 6:00 AM, US Eastern Standard Time on Apr 21, 2026お知らせ • Feb 25Danaher Corporation Announces Quarterly Dividend, Payable on April 24, 2026Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 24, 2026 to holders of record on March 27, 2026.お知らせ • Feb 17+ 1 more updateDanaher Corporation (NYSE:DHR) entered into a definitive agreement to acquire Masimo Corporation (NasdaqGS:MASI) from Politan Capital Management, L.P for $9.5 billion.Danaher Corporation (NYSE:DHR) entered into a definitive agreement to acquire Masimo Corporation (NasdaqGS:MASI) from Politan Capital Management, L.P for $9.5 billion on February 16, 2026. Masimo will become a standalone business unit and brand within Danaher’s Diagnostics segment and will operate autonomously while strengthening Danaher’s offering in acute care settings. In case of termination Masimo will pay $305 million. Danaher expects to fund the acquisition using cash on hand and proceeds from debt financing. The Transaction has been unanimously approved by both Masimo’s Board of Directors and Danaher’s Board of Directors and is subject to the satisfaction or waiver of certain closing conditions, including the receipt of required regulatory approvals, Masimo shareholders approval, HSR act approval. The merger is expected to close in the second half of 2026. Masimo is expected to be accretive to adjusted diluted net earnings per common share by $0.15 to $0.20 in the first full year and approximately $0.70 in the fifth full year following completion of the acquisition. Centerview Partners LLC acted as financial advisor for Masimo Corporation. Morgan Stanley & Co. LLC acted as financial advisor for Masimo Corporation. Lauren S. Boehmke and Melissa Sawyer of Sullivan & Cromwell LLP acted as legal advisor for Masimo Corporation. Matthew Barnett and Richard Brand of White & Case LLP acted as legal advisor for Masimo Corporation. David M. Klein, Daniel E. Wolf, Adam Petravicius, Joanna Schlingbaum, Ellisen Shelton Turner, Jordan D. Peterson, Scott D. Price, David G. Branham, Maddison M. Riddick, Rachael L. Lichman, Joshua N. Korff, Diahndra Burman, Liam N. Murphy and Dean S. Shulman of Kirkland & Ellis LLP acted as legal advisor for Danaher Corporation. Longacre Square Partners acted as strategy and communications advisor to Masimo. Citigroup Inc. (NYSE:C) acted as financial advisor to Danaher Corporation.お知らせ • Feb 11Danaher Corporation Announces Retirement of Director, Jessica L. Mega, Effective February 5, 2026Danaher Corporation announced that Jessica L. Mega notified the Board of Directors of her retirement from the Board as of February 5, 2026, due to commitments related to her other professional obligations. Dr. Mega's decision was not the result of any disagreement with Danaher on any matter relating to Danaher's operations, policies or practices.Reported Earnings • Jan 29Full year 2025 earnings released: EPS: US$5.05 (vs US$5.33 in FY 2024)Full year 2025 results: EPS: US$5.05 (down from US$5.33 in FY 2024). Revenue: US$24.6b (up 2.9% from FY 2024). Net income: US$3.60b (down 7.7% from FY 2024). Profit margin: 15% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.お知らせ • Dec 17Danaher Corporation to Report Q4, 2025 Results on Jan 28, 2026Danaher Corporation announced that they will report Q4, 2025 results at 6:00 AM, US Eastern Standard Time on Jan 28, 2026Declared Dividend • Dec 12Dividend of US$0.32 announcedShareholders will receive a dividend of US$0.32. Ex-date: 23rd December 2025 Payment date: 30th January 2026 Dividend yield will be 0.4%, which is about the same as the industry average. Payout Ratios Payout ratio: 25%. Cash payout ratio: 18%.お知らせ • Dec 10Danaher Corporation Announces Quarterly Dividend, Payable on January 30, 2026Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on January 30, 2026 to holders of record on December 26, 2025.Recent Insider Transactions • Nov 27Co-Founder & Director recently sold €8.1m worth of stockOn the 25th of November, Mitchell Rales sold around 41k shares on-market at roughly €199 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €112m. Mitchell has been a net seller over the last 12 months, reducing personal holdings by €203m.Recent Insider Transactions • Nov 14Co-Founder & Director recently sold €82m worth of stockOn the 12th of November, Mitchell Rales sold around 437k shares on-market at roughly €189 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €112m. Mitchell has been a net seller over the last 12 months, reducing personal holdings by €195m.お知らせ • Nov 08Danaher Corporation Announces Retirement of John T. Schwieters from Its BoardDanaher Corporation announced on November 6, 2025, John T. Schwieters notified the company’s Board of Directors that he has decided not to stand for reelection at the Company’s 2026 annual meeting of shareholders (“2026 Annual Meeting”), and will retire from the Danaher Board as of the 2026 Annual Meeting. Mr. Schwieters’ decision was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The size of the Board will be reduced from thirteen to twelve members as of the time of Mr. Schwieters’ retirement.Recent Insider Transactions • Nov 05Co-Founder & Director recently sold €112m worth of stockOn the 31st of October, Mitchell Rales sold around 600k shares on-market at roughly €187 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Mitchell's only on-market trade for the last 12 months.Reported Earnings • Oct 27Third quarter 2025 earnings released: EPS: US$1.28 (vs US$1.13 in 3Q 2024)Third quarter 2025 results: EPS: US$1.28 (up from US$1.13 in 3Q 2024). Revenue: US$6.05b (up 4.4% from 3Q 2024). Net income: US$908.0m (up 11% from 3Q 2024). Profit margin: 15% (in line with 3Q 2024). Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.お知らせ • Oct 22Danaher Corporation Provides Revenue Guidance for the Fourth Quarter of 2025 and for the Full Year 2026Danaher Corporation provided revenue guidance for the fourth quarter of 2025 and for the full year 2026. In the fourth quarter, the company expects core revenue to grow in the low single-digit percent range as it expects market conditions to be largely consistent with what the company saw in third quarter. For the full year 2026, the company expects core revenue growth in the 3% to 6% range as it is assuming modest recovery across end markets.お知らせ • Sep 24Danaher Corporation to Report Q3, 2025 Results on Oct 21, 2025Danaher Corporation announced that they will report Q3, 2025 results at 6:00 AM, Eastern Standard Time on Oct 21, 2025お知らせ • Sep 10Danaher Announces Quarterly Dividend, Payable on October 31, 2025Danaher Corporation has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on October 31, 2025 to holders of record on September 26, 2025.お知らせ • Aug 01Danaher Corporation Announces Executive ChangesDanaher Corporation announced that Jonathan Leiken has been appointed Senior Vice President and General Counsel, effective August 25, 2025. Mr. Leiken will report directly to President and Chief Executive Officer Rainer Blair and will serve as an executive officer and a member of the Danaher Leadership Team. Jonathan Leiken succeeds Brian Ellis, who will retire after nearly a decade of distinguished service as Danaher's General Counsel. Mr. Ellis will remain at Danaher in an executive officer role through February 2026 to support the transition. Prior to joining Danaher, Mr. Leiken served as Executive Vice President, Chief Legal Officer, and Corporate Secretary at Dollar Tree Inc., a Fortune 150 company, where he oversaw corporate governance, ethics and compliance, sustainability and regulatory affairs. Prior to that, he held the same role at Diebold Nixdorf Inc., a global technology company, where he also led intellectual property, internal audit and ESG functions. Mr. Leiken's career includes serving as a federal prosecutor in the U.S. Attorney's Office for the Southern District of New York, where he was recognized for superior performance by multiple federal agencies. He has also been a partner at a global law firm, advising Fortune 500 companies and major institutions on complex litigation, corporate strategy and regulatory matters. He holds a J.D., cum laude, from the University of Pennsylvania Law School and a B.A. in Political Science, magna cum laude, from Brandeis University.お知らせ • Jul 22Danaher Corporation Announces Chief Financial Officer Changes, Effective February 28 , 2026Danaher Corporation announced that Matthew Gugino, currently Group Chief Financial Officer of the Company's Life Sciences Innovations Group and Vice President of Financial Planning & Analysis, will succeed Matthew McGrew as Danaher's Chief Financial Officer effective February 28th, 2026. Following the transition and consistent with past practice, Mr. McGrew will continue thereafter as an Executive Vice President of the Company, as he begins a gradual transition to retirement, after more than 20 years with Danaher. Mr. McGrew has served as Danaher's CFO since January 2019. He joined Danaher in 2004 as Director, M&A Finance and served in roles of increasing responsibility including Vice President, Investor Relations from 2009 to 2014 and as a Danaher Group CFO from 2012 to 2018. During his tenure as CFO, Danaher meaningfully increased its growth and margin profile, and nearly doubled both its revenue and market capitalization. Mr. Gugino joined Danaher in 2013 as Director, Investor Relations and served as Vice President, Investor Relations from 2014 to 2022. He has served as Vice President of Financial Planning & Analysis since 2019 and additionally as Group Chief Financial Officer in the Company's Life Sciences Innovations Group since 2021. Prior to joining Danaher, he was a Vice President of Equity Research at Barclays and Morgan Stanley, and an Associate at KPMG. He holds a Bachelor of Science degree in Accounting and a Master of Accountancy and Professional Consultancy from Villanova University.お知らせ • Jun 28Danaher Corporation(NYSE:DHR) dropped from Russell Top 50 IndexDanaher Corporation(NYSE:DHR) dropped from Russell Top 50 Indexお知らせ • Jun 27+ 1 more updateDanaher Corporation Appoints Greg Milosevich to Executive Vice President, Life Sciences Business, Effective July 1, 2025Danaher Corporation announced that Greg Milosevich has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Life Sciences business, effective July 1, 2025. Mr. Milosevich has served as Vice President and Group Executive of the Life Sciences Innovations Group since 2021. With this expanded role, he will become an executive officer of Danaher and will continue reporting to Rainer Blair, President and Chief Executive Officer. Mr. Milosevich joined Danaher in 2010, through the acquisition of Molecular Devices, and since has held roles of increasing responsibility across multiple businesses. In his most recent role, as Vice President and Group Executive, Life Sciences Innovations Group, Mr. Milosevich oversaw multiple Danaher companies, including Beckman Coulter Life Sciences, Sciex, Leica Microsystems, Molecular Devices, Phenomenex, Abcam, IDBS and Genedata. He holds a bachelor's degree in physics from the University of Puget Sound, graduating Summa Cum Laude.お知らせ • Jun 18Danaher Corporation to Report Q2, 2025 Results on Jul 22, 2025Danaher Corporation announced that they will report Q2, 2025 results at 6:00 AM, US Eastern Standard Time on Jul 22, 2025お知らせ • May 07Danaher Announces Regular Quarterly Dividend, Payable on July 25, 2025Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on July 25, 2025 to holders of record on June 27, 2025.Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €157, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 17x in the Life Sciences industry in Europe. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €191 per share.Buy Or Sell Opportunity • Apr 05Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 24% to €171. The fair value is estimated to be €220, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 8.6% over the last 3 years. Earnings per share has declined by 19%. For the next 3 years, revenue is forecast to grow by 5.5% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.お知らせ • Mar 28Danaher Corporation, Annual General Meeting, May 06, 2025Danaher Corporation, Annual General Meeting, May 06, 2025.株主還元1DHRIT Life SciencesIT 市場7D3.7%4.8%-1.1%1Y-9.3%-7.5%17.6%株主還元を見る業界別リターン: 1DHR過去 1 年間で-7.5 % のリターンをもたらしたItalian Life Sciences業界と一致しました。リターン対市場: 1DHRは、過去 1 年間で17.6 % のリターンを上げたItalian市場を下回りました。価格変動Is 1DHR's price volatile compared to industry and market?1DHR volatility1DHR Average Weekly Movement4.7%Life Sciences Industry Average Movement7.5%Market Average Movement5.1%10% most volatile stocks in IT Market8.4%10% least volatile stocks in IT Market3.2%安定した株価: 1DHR 、 Italian市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 1DHRの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト196959,000Rainer Blairwww.danaher.comダナハーコーポレーションは、米国、中国、および国際的に、専門的、医療、研究、産業用製品およびサービスの設計、製造、販売を行っている。バイオテクノロジー、ライフサイエンス、ダイアグノスティックスの各セグメントで事業を展開。バイオテクノロジー事業では、治療薬の開発・製造を促進、加速、統合するバイオプロセス技術、消耗品、サービス、ソリューション、細胞株および細胞培養培地開発サービス、細胞培養培地、製造用プロセス液および緩衝液、クロマトグラフィー樹脂、ろ過技術、無菌充填仕上げを提供している；シングルユースハードウェア、消耗品およびサービス（完全な製造スイートの設計および設置など）、ラボのろ過、分離、精製、ラボスケールのタンパク質精製および分析ツール、診断およびアッセイ開発用の試薬、メンブレンおよびサービス、ヘルスケアろ過ソリューション。ライフサイエンス事業は、質量分析計、バイオ分析測定システム、フローサイトメトリー、ゲノミクス、ラボオートメーション、遠心分離、リキッドハンドリングオートメーション機器、抗体、粒子計測と特性評価、ゲノムサンプル調製、顕微鏡を提供している；ABCAM、ALDEVRON、BECKMAN COULTER、GENEDATA、IDT、LEICA MICROSYSTEMS、MOLECULAR DEVICES、PALL、PHENOMENEX、SCIEXブランドのカスタム核酸製品、プラスミドDNA、RNA、タンパク質などのゲノム医薬品。Diagnostics部門は、臨床化学、免疫測定、血液学、微生物学の分野における臨床機器、消耗品、ソフトウェア、サービスを病院、医院、レファレンス・ラボラトリー、その他のクリティカルケア施設向けに提供している。以前はDiversified Mortgage Investors, Inc.として知られ、1984年にダナハーコーポレーションに社名を変更した。ダナハーコーポレーションは1969年に設立され、本社はコロンビア特別区ワシントンにある。もっと見るDanaher Corporation 基礎のまとめDanaher の収益と売上を時価総額と比較するとどうか。1DHR 基礎統計学時価総額€104.25b収益（TTM）€3.16b売上高(TTM)€21.33b33.4xPER（株価収益率5.0xP/Sレシオ1DHR は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計1DHR 損益計算書（TTM）収益US$24.78b売上原価US$10.16b売上総利益US$14.62bその他の費用US$10.94b収益US$3.68b直近の収益報告Mar 27, 2026次回決算日該当なし一株当たり利益（EPS）5.19グロス・マージン58.99%純利益率14.83%有利子負債／自己資本比率34.9%1DHR の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.9%現在の配当利回り26%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 08:12終値2026/05/21 00:00収益2026/03/27年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Danaher Corporation 22 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。44 アナリスト機関John EadeArgus Research CompanyCatherine Ramsey SchulteBairdLuke SergottBarclays41 その他のアナリストを表示
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 7 highly experienced directors. Independent Director A. Sanders was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 07Danaher Corporation announces Quarterly dividend, payable on July 31, 2026Danaher Corporation announced Quarterly dividend of USD 0.4000 per share payable on July 31, 2026, ex-date on June 26, 2026 and record date on June 26, 2026.
Buy Or Sell Opportunity • Mar 29Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 19% to €159. The fair value is estimated to be €199, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 18%. For the next 3 years, revenue is forecast to grow by 5.8% per annum. Earnings are also forecast to grow by 15% per annum over the same time period.
お知らせ • Mar 26Danaher Corporation, Annual General Meeting, May 05, 2026Danaher Corporation, Annual General Meeting, May 05, 2026.
お知らせ • Mar 21Danaher Corporation to Report Q1, 2026 Results on Apr 21, 2026Danaher Corporation announced that they will report Q1, 2026 results at 6:00 AM, US Eastern Standard Time on Apr 21, 2026
お知らせ • Feb 25Danaher Corporation Announces Quarterly Dividend, Payable on April 24, 2026Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 24, 2026 to holders of record on March 27, 2026.
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 7 highly experienced directors. Independent Director A. Sanders was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 07Danaher Corporation announces Quarterly dividend, payable on July 31, 2026Danaher Corporation announced Quarterly dividend of USD 0.4000 per share payable on July 31, 2026, ex-date on June 26, 2026 and record date on June 26, 2026.
Buy Or Sell Opportunity • Mar 29Now 20% undervalued after recent price dropOver the last 90 days, the stock has fallen 19% to €159. The fair value is estimated to be €199, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 18%. For the next 3 years, revenue is forecast to grow by 5.8% per annum. Earnings are also forecast to grow by 15% per annum over the same time period.
お知らせ • Mar 26Danaher Corporation, Annual General Meeting, May 05, 2026Danaher Corporation, Annual General Meeting, May 05, 2026.
お知らせ • Mar 21Danaher Corporation to Report Q1, 2026 Results on Apr 21, 2026Danaher Corporation announced that they will report Q1, 2026 results at 6:00 AM, US Eastern Standard Time on Apr 21, 2026
お知らせ • Feb 25Danaher Corporation Announces Quarterly Dividend, Payable on April 24, 2026Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.40 per share of its common stock, payable on April 24, 2026 to holders of record on March 27, 2026.
お知らせ • Feb 17+ 1 more updateDanaher Corporation (NYSE:DHR) entered into a definitive agreement to acquire Masimo Corporation (NasdaqGS:MASI) from Politan Capital Management, L.P for $9.5 billion.Danaher Corporation (NYSE:DHR) entered into a definitive agreement to acquire Masimo Corporation (NasdaqGS:MASI) from Politan Capital Management, L.P for $9.5 billion on February 16, 2026. Masimo will become a standalone business unit and brand within Danaher’s Diagnostics segment and will operate autonomously while strengthening Danaher’s offering in acute care settings. In case of termination Masimo will pay $305 million. Danaher expects to fund the acquisition using cash on hand and proceeds from debt financing. The Transaction has been unanimously approved by both Masimo’s Board of Directors and Danaher’s Board of Directors and is subject to the satisfaction or waiver of certain closing conditions, including the receipt of required regulatory approvals, Masimo shareholders approval, HSR act approval. The merger is expected to close in the second half of 2026. Masimo is expected to be accretive to adjusted diluted net earnings per common share by $0.15 to $0.20 in the first full year and approximately $0.70 in the fifth full year following completion of the acquisition. Centerview Partners LLC acted as financial advisor for Masimo Corporation. Morgan Stanley & Co. LLC acted as financial advisor for Masimo Corporation. Lauren S. Boehmke and Melissa Sawyer of Sullivan & Cromwell LLP acted as legal advisor for Masimo Corporation. Matthew Barnett and Richard Brand of White & Case LLP acted as legal advisor for Masimo Corporation. David M. Klein, Daniel E. Wolf, Adam Petravicius, Joanna Schlingbaum, Ellisen Shelton Turner, Jordan D. Peterson, Scott D. Price, David G. Branham, Maddison M. Riddick, Rachael L. Lichman, Joshua N. Korff, Diahndra Burman, Liam N. Murphy and Dean S. Shulman of Kirkland & Ellis LLP acted as legal advisor for Danaher Corporation. Longacre Square Partners acted as strategy and communications advisor to Masimo. Citigroup Inc. (NYSE:C) acted as financial advisor to Danaher Corporation.
お知らせ • Feb 11Danaher Corporation Announces Retirement of Director, Jessica L. Mega, Effective February 5, 2026Danaher Corporation announced that Jessica L. Mega notified the Board of Directors of her retirement from the Board as of February 5, 2026, due to commitments related to her other professional obligations. Dr. Mega's decision was not the result of any disagreement with Danaher on any matter relating to Danaher's operations, policies or practices.
Reported Earnings • Jan 29Full year 2025 earnings released: EPS: US$5.05 (vs US$5.33 in FY 2024)Full year 2025 results: EPS: US$5.05 (down from US$5.33 in FY 2024). Revenue: US$24.6b (up 2.9% from FY 2024). Net income: US$3.60b (down 7.7% from FY 2024). Profit margin: 15% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
お知らせ • Dec 17Danaher Corporation to Report Q4, 2025 Results on Jan 28, 2026Danaher Corporation announced that they will report Q4, 2025 results at 6:00 AM, US Eastern Standard Time on Jan 28, 2026
Declared Dividend • Dec 12Dividend of US$0.32 announcedShareholders will receive a dividend of US$0.32. Ex-date: 23rd December 2025 Payment date: 30th January 2026 Dividend yield will be 0.4%, which is about the same as the industry average. Payout Ratios Payout ratio: 25%. Cash payout ratio: 18%.
お知らせ • Dec 10Danaher Corporation Announces Quarterly Dividend, Payable on January 30, 2026Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on January 30, 2026 to holders of record on December 26, 2025.
Recent Insider Transactions • Nov 27Co-Founder & Director recently sold €8.1m worth of stockOn the 25th of November, Mitchell Rales sold around 41k shares on-market at roughly €199 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €112m. Mitchell has been a net seller over the last 12 months, reducing personal holdings by €203m.
Recent Insider Transactions • Nov 14Co-Founder & Director recently sold €82m worth of stockOn the 12th of November, Mitchell Rales sold around 437k shares on-market at roughly €189 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger sale worth €112m. Mitchell has been a net seller over the last 12 months, reducing personal holdings by €195m.
お知らせ • Nov 08Danaher Corporation Announces Retirement of John T. Schwieters from Its BoardDanaher Corporation announced on November 6, 2025, John T. Schwieters notified the company’s Board of Directors that he has decided not to stand for reelection at the Company’s 2026 annual meeting of shareholders (“2026 Annual Meeting”), and will retire from the Danaher Board as of the 2026 Annual Meeting. Mr. Schwieters’ decision was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The size of the Board will be reduced from thirteen to twelve members as of the time of Mr. Schwieters’ retirement.
Recent Insider Transactions • Nov 05Co-Founder & Director recently sold €112m worth of stockOn the 31st of October, Mitchell Rales sold around 600k shares on-market at roughly €187 per share. This transaction amounted to 1.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Mitchell's only on-market trade for the last 12 months.
Reported Earnings • Oct 27Third quarter 2025 earnings released: EPS: US$1.28 (vs US$1.13 in 3Q 2024)Third quarter 2025 results: EPS: US$1.28 (up from US$1.13 in 3Q 2024). Revenue: US$6.05b (up 4.4% from 3Q 2024). Net income: US$908.0m (up 11% from 3Q 2024). Profit margin: 15% (in line with 3Q 2024). Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
お知らせ • Oct 22Danaher Corporation Provides Revenue Guidance for the Fourth Quarter of 2025 and for the Full Year 2026Danaher Corporation provided revenue guidance for the fourth quarter of 2025 and for the full year 2026. In the fourth quarter, the company expects core revenue to grow in the low single-digit percent range as it expects market conditions to be largely consistent with what the company saw in third quarter. For the full year 2026, the company expects core revenue growth in the 3% to 6% range as it is assuming modest recovery across end markets.
お知らせ • Sep 24Danaher Corporation to Report Q3, 2025 Results on Oct 21, 2025Danaher Corporation announced that they will report Q3, 2025 results at 6:00 AM, Eastern Standard Time on Oct 21, 2025
お知らせ • Sep 10Danaher Announces Quarterly Dividend, Payable on October 31, 2025Danaher Corporation has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on October 31, 2025 to holders of record on September 26, 2025.
お知らせ • Aug 01Danaher Corporation Announces Executive ChangesDanaher Corporation announced that Jonathan Leiken has been appointed Senior Vice President and General Counsel, effective August 25, 2025. Mr. Leiken will report directly to President and Chief Executive Officer Rainer Blair and will serve as an executive officer and a member of the Danaher Leadership Team. Jonathan Leiken succeeds Brian Ellis, who will retire after nearly a decade of distinguished service as Danaher's General Counsel. Mr. Ellis will remain at Danaher in an executive officer role through February 2026 to support the transition. Prior to joining Danaher, Mr. Leiken served as Executive Vice President, Chief Legal Officer, and Corporate Secretary at Dollar Tree Inc., a Fortune 150 company, where he oversaw corporate governance, ethics and compliance, sustainability and regulatory affairs. Prior to that, he held the same role at Diebold Nixdorf Inc., a global technology company, where he also led intellectual property, internal audit and ESG functions. Mr. Leiken's career includes serving as a federal prosecutor in the U.S. Attorney's Office for the Southern District of New York, where he was recognized for superior performance by multiple federal agencies. He has also been a partner at a global law firm, advising Fortune 500 companies and major institutions on complex litigation, corporate strategy and regulatory matters. He holds a J.D., cum laude, from the University of Pennsylvania Law School and a B.A. in Political Science, magna cum laude, from Brandeis University.
お知らせ • Jul 22Danaher Corporation Announces Chief Financial Officer Changes, Effective February 28 , 2026Danaher Corporation announced that Matthew Gugino, currently Group Chief Financial Officer of the Company's Life Sciences Innovations Group and Vice President of Financial Planning & Analysis, will succeed Matthew McGrew as Danaher's Chief Financial Officer effective February 28th, 2026. Following the transition and consistent with past practice, Mr. McGrew will continue thereafter as an Executive Vice President of the Company, as he begins a gradual transition to retirement, after more than 20 years with Danaher. Mr. McGrew has served as Danaher's CFO since January 2019. He joined Danaher in 2004 as Director, M&A Finance and served in roles of increasing responsibility including Vice President, Investor Relations from 2009 to 2014 and as a Danaher Group CFO from 2012 to 2018. During his tenure as CFO, Danaher meaningfully increased its growth and margin profile, and nearly doubled both its revenue and market capitalization. Mr. Gugino joined Danaher in 2013 as Director, Investor Relations and served as Vice President, Investor Relations from 2014 to 2022. He has served as Vice President of Financial Planning & Analysis since 2019 and additionally as Group Chief Financial Officer in the Company's Life Sciences Innovations Group since 2021. Prior to joining Danaher, he was a Vice President of Equity Research at Barclays and Morgan Stanley, and an Associate at KPMG. He holds a Bachelor of Science degree in Accounting and a Master of Accountancy and Professional Consultancy from Villanova University.
お知らせ • Jun 28Danaher Corporation(NYSE:DHR) dropped from Russell Top 50 IndexDanaher Corporation(NYSE:DHR) dropped from Russell Top 50 Index
お知らせ • Jun 27+ 1 more updateDanaher Corporation Appoints Greg Milosevich to Executive Vice President, Life Sciences Business, Effective July 1, 2025Danaher Corporation announced that Greg Milosevich has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its Life Sciences business, effective July 1, 2025. Mr. Milosevich has served as Vice President and Group Executive of the Life Sciences Innovations Group since 2021. With this expanded role, he will become an executive officer of Danaher and will continue reporting to Rainer Blair, President and Chief Executive Officer. Mr. Milosevich joined Danaher in 2010, through the acquisition of Molecular Devices, and since has held roles of increasing responsibility across multiple businesses. In his most recent role, as Vice President and Group Executive, Life Sciences Innovations Group, Mr. Milosevich oversaw multiple Danaher companies, including Beckman Coulter Life Sciences, Sciex, Leica Microsystems, Molecular Devices, Phenomenex, Abcam, IDBS and Genedata. He holds a bachelor's degree in physics from the University of Puget Sound, graduating Summa Cum Laude.
お知らせ • Jun 18Danaher Corporation to Report Q2, 2025 Results on Jul 22, 2025Danaher Corporation announced that they will report Q2, 2025 results at 6:00 AM, US Eastern Standard Time on Jul 22, 2025
お知らせ • May 07Danaher Announces Regular Quarterly Dividend, Payable on July 25, 2025Danaher Corporation announced that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common stock, payable on July 25, 2025 to holders of record on June 27, 2025.
Valuation Update With 7 Day Price Move • Apr 09Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to €157, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 17x in the Life Sciences industry in Europe. Total loss to shareholders of 31% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €191 per share.
Buy Or Sell Opportunity • Apr 05Now 22% undervalued after recent price dropOver the last 90 days, the stock has fallen 24% to €171. The fair value is estimated to be €220, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 8.6% over the last 3 years. Earnings per share has declined by 19%. For the next 3 years, revenue is forecast to grow by 5.5% per annum. Earnings are also forecast to grow by 12% per annum over the same time period.
お知らせ • Mar 28Danaher Corporation, Annual General Meeting, May 06, 2025Danaher Corporation, Annual General Meeting, May 06, 2025.
